Wednesday, April 14, 2021 Evaluate the ability to predict survival benefit from adjuvant chemotherapy in early stage non-small cell lung cancer (NSCLC), and LACE-BIO (JBR.10) and Correlative Science Fung AS, Karimi M, Michiels S, Seymour L, Brambilla E, Le-Chevalier T, Soria JC, Kratzke R, Graziano SL, Devarakonda S, Govindan R, Tsao MS, Shepherd FA, Collaborative Group obotL-B. Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. Translational Lung Cancer Research 10: 826-38, 21 A.D. https://tlcr.amegroups.com/article/view/49499/html The current LACE-Bio analysis showed that concomitant KRAS mutations and copy number gain are rare, occurring in approximately 4% of NSCLC patients. Although not significant, there was a trend towards worse LCSS, DFS and OS in KRAS MUT + Gain patients relative to WT + Neut/Loss patients. In addition, concomitant KRAS mutation and CN gain appeared to predict for better DFS in adenocarcinoma patients treated with adjuvant chemotherapy, with a trend towards better LCSS and OS as well. However, these results could be driven by the small number of patients and require further validation.
